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Abstract
Background—The Sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor
(β1AR) are G protein-coupled receptors (GPCRs) expressed in the heart. These two GPCRs have
opposing actions on adenylyl cyclase due to differential G protein-coupling. Importantly, both of
these receptors can be regulated by the actions of GPCR kinase-2 (GRK2), which triggers
desensitization and down-regulation processes. Although, classical signaling paradigms suggest
that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply be opposing action
on cAMP production, in this report we have uncovered a direct interaction between these two
receptors with a regulatory involvement of GRK2.
Methods and Results—In HEK293 cells overexpressing both β1AR and S1PR1, we
demonstrate that β1AR down-regulation can occur after sphingosine 1-phosphate (S1PR1 agonist)
stimulation while S1PR1 down-regulation can be triggered by isoproterenol (βAR agonist)
treatment. This cross-talk between these two distinct GPCRs appears to have physiological
significance since they interact and show reciprocal regulation in mouse hearts undergoing chronic
βAR stimulation and also in a rat model of post-ischemic heart failure (HF).
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Conclusions—We demonstrate that restoring cardiac plasma membrane levels of S1PR1
produce beneficial effects counterbalancing deleterious β1AR overstimulation in HF.
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Introduction
G protein-coupled receptors (GPCRs) transduce cell signals via heterotrimeric G proteins
from neurohormones, ions, and sensory stimuli to regulate every aspect of mammalian
physiology. GPCRs are regulated by GPCR kinases (GRKs) that trigger termination of
signaling, a process known as desensitization. Phosphorylation of agonist-occupied
receptors by GRKs induces recruitment and binding of β-arrestins that displace bound G
proteins, therefore uncoupling receptors from their downstream signaling effectors. This
process continues through β-arrestin-dependent internalization of receptors, that lead either
to their degradation and down-regulation or recycling (resensitization) to the membrane.
Moreover, β-arrestin recruitment to GRK-phosphorylated receptors has been shown to lead
to novel intracellular signaling, a process called G protein-independent signaling1. In the
heart, an important GRK-mediated β-arrestin-dependent signal has been shown to be ERK
MAP kinase activation2. Given the central role in cardiac pathophysiology, GPCRs are
critical therapeutic targets in cardiac diseases. This is especially true in heart failure (HF)
where β-adrenergic receptor (βAR) antagonists and angiotensin II receptor blockers are
standard of care for human HF patients.
βAR and angiotensin II receptor blockade are warranted as a consequence of the
sympathetic nervous system (SNS) and renin-angiotensin system (RAS) hyperactivity that
induces their overstimlation. This phenomenon represents the molecular basis for βAR
down-regulation in the failing human myocardium. Since GPCRs are dynamically regulated
in disease processes a better understanding of down-stream signaling is imperative. In
particular, GPCR dimerization3 and interaction between different GPCR signaling
pathways4,5 have become the cornerstone of current cardiovascular research in order to
better clarify molecular alterations underlying cardiovascular diseases and to identify novel
potential therapeutic targets. In cardiac physiology and pathophysiology, the β1AR is the
predominant βAR that regulates inotropic and chronotropic responses of SNS
catecholamines through Gs-dependent activation of adenylyl cyclase (AC)6,7. Chronic β1AR
hyperstimulation results in their down-regulation and consequently there is a marked
reduction of the inotropic reserve of the failing heart8,9. The sphingosine-1-phosphate
receptor 1 (S1PR1), which mediates the effect of the lysophospholipid sphingosine-1-
phosphate (S1P, a natural agonist) is also expressed on cardiomyocytes10 and its signaling
opposes β1AR-mediated AC activation through its coupling to the AC-inhibitory G protein,
Gi11. Thus, in the heart, S1PR1 is able to antagonize the effects mediated by isoproterenol
(ISO) and other βAR agonists11,12. Furthermore, S1PR1 and β1AR undergo GRK-mediated
regulation through phosphorylation13,14,15. Although GRK2, the primary GRK isoform
expressed in myocytes, can regulate both receptors, the β1AR is also regulated by
phosphorylation by protein kinase A (PKA)13,14, while the S1PR1 can be regulated by
protein kinase C (PKC)15. Importantly, in respect to novel non-canonical signaling both
receptors have been implicated in ERK activation that can lead to protective signaling2.
Recently, a functional interaction between βAR and S1PR1 signaling has been reported in
vivo. In fact, ISO administration in mice induces cardiac hypertrophy via engagement of the
S1PR1 signaling pathway12. However, there is no proof of direct cross-talk at the receptor
level between β1ARs and S1PR1s. In the present study, we provide biochemical and
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functional evidence of a direct connection between these two highly expressed GPCRs in the
heart, demonstrating their reciprocal regulation via an important regulator, GRK2, which has
potential significance for cardiac pathophysiology.
Methods
Cell Culture
Human embryonic kidney (HEK) 293 cells overepressing the mouse wild type β1AR
carrying a Flag epitope (WTβ1AR-Flag) or 2 mutants lacking, respectively: the putative
PKA phosphorylation sites (PKA-β1AR-Flag) and the putative GRK phosphorylation sites
(GRK-β1AR-Flag) obtained as previously described14 and cardiomyoblasts H9c2 obtained
from American Type Culture Collection (ATCC), were cultured and transfected as briefly
described in online methods.
Confocal microscopy
S1PR1-GFP and β1AR-Flag internalization was visualized by confocal laser scanning
microscopy (CLSM). Following (−)-isoproterenol bitartrate (ISO, 1 μM; Sigma-Aldrich) or
sphingosine-1 phosphate (S1P, 250 nM; Sigma-Aldrich) stimulation cells were fixed and
visualized as previously described (16). After fixation cells were incubated with an anti-Flag
Cy3 conjugated mouse IgG (Sigma-Aldrich) using a diluition 1:100 in PBS containing 0.5%
BSA for 1h at room temperature. CLSM was performed at 488 nm (GFP) or 568 nm (Cy3).
The fluorescent data sets were analyzed by LSM 510 software. The cells treated with ISO
were pre-treated with selective β2AR-antagonist ICI-118,551-HCl (ICI, 10 μM; Sigma-
Aldrich). Each experiment was separately repeated at least three times.
Immunoblotting
Immunoblotting on cells and left ventricular (LV) samples were performed as previously
described16 and briefly reported in the online supplemental methods.
Treatment protocol for mice
As previously described2,17,18, C57BL/6 mice (n=5) were subcutaneously injected, twice a
day, with ISO, dissolved in 0.002% ascorbic acid, at the total rate of 3 mg/kg/d over a period
of 7 days. Control mice (SHAM, n=5) were injected with vehicle (0.002% ascorbic acid). At
sacrifice, after heart weight (HW) and body weight (BW) ratio calculation, the hearts were
removed and cardiac chambers dissected.
Measurement of hypertrophic growth in H9c2 cardiomyoblasts
Hypertrophy was assessed by measurement of relative cell surface area of H9c2 cells as
previously described19,20,21 (please see online supplemental methods).
TUNEL staining
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) was
performed on H9C2 cells (please see online supplemental methods).
Rat MI model
Myocardial infarction (MI) in rats was performed as previously described22 and briefly
reported in the online supplemental methods.
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Myocardial in vivo gene delivery
Myocardial gene transfer in rats was achieved by direct intra-myocardial injection 8 weeks
post-MI as previously described23 and briefly reported in the online supplemental methods.
Echocardiography
Echocardiography was performed as previously described22,24 and briefly reported in the
online supplemental methods.
Catheter-based in vivo hemodynamic measurements
Cardiac function was measured 12 weeks following gene therapy as previously described23.
Myocardial perfusion studies
Myocardial perfusion was determined using 15 μm fluorescent microspheres (Triton Inc.).
Cardiac and blood samples were processed for microspheres determination. Myocardial
blood flow was measured basal and after maximal vasodilation with dipyridamole (6 mg
kg-1 min-1 i.v.).
Measurement of infarct size
Infarct size was examined in all experimental rats at the end of the study period, as
previously described23 and briefly reported in the online supplemental methods.
Histology
Left ventricular paraffin embedded specimens were immunohistochemically stained for
S1PR1 (anti-S1PR1 mouse monoclonal, 1:100; abm) and GFP (anti-GFP mouse
monoclonal, 1:200; Upstate) or stained for capillary density determination as previously
described16 and briefly reported in online methods.
RT-PCR
Total RNA was isolated from cardiac samples using TRIzol reagent (invitrogen) according
to the manufacturer’s instructions and was reversed transcribed to generate cDNA. To
evaluate the expression of recombinant human S1PR1-GFP and GFP was performed a PCR
using specific primers (hS1PR1-For 5′-CAGCAAATCGGACAATTCCT-3′, hS1PR1-Rev
5′-GAACTTCAGGGTCAGCTTGC-3′ GFP-For 5′-GACGTAAACGGCCACAAGTT-3′
GFP-Rev 5′-AAGTCGTGCTGCTTCATGTG-3′) with respectively amplified products of
250 bp and 180 bp.
β-Adrenergic Receptor Radioligand Binding
Receptor binding with 20 μg of protein from plasma membrane was performed using
[125I]cyanopindolol (350 pM) as previously described24. Receptor density (fmol) was
normalized to milligrams of membrane protein.
Statistical analysis
Normally distributed, continuous variables with sample size greater than 10 are expressed as
mean ± SEM and compared by one-way or repeated measures ANOVA test followed by
Bonferroni post hoc correction, as appropriate. When sample size was less than 10, exact
tests (Mann-Whitney or Kruskal-Wallis as required), followed by Bonferroni post hoc
correction, were performed and data represented with median and dot plots. Normality was
tested using Shapiro-Wilk test (<50 values) or Kolmorov-Smirnov test (≥50 values), as
appropriate. All analyzed data showed no significant departure from normal distribution.
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Statistical Analysis was performed using SPSS software (SPSS Inc., Chicago, Illinois).
Level of statistical significance was set top ≤ 0.05.
Results
In vitro reciprocal downregulation of β1AR and S1PR1
In order to establish a functional correlation between β1AR and S1PR1 signaling, HEK293
cells stably expressing the mouse wild-type β1AR (WTβ1AR) or 2 mutants lacking,
respectively: the putative PKA phosphorylation sites (PKA-β1AR) or the putative GRK
phosphorylation sites (GRK-β1AR) were transfected with S1PR1 cDNA. By confocal
microscopy experiments we evaluated β1AR and S1PR1 internalization following ISO and
S1P stimulation. As shown in Figure 1A, ISO and S1P stimulations resulted in a marked loss
of both WTβ1AR and S1PR1 from the cell surface and surprisingly, in a co-localization of
the two receptors in the cytosol peaking after 30 min of treatment. The absence of PKA
phosphorylation sites (PKA-β1AR) did not affect the reciprocal internalization and cytosolic
co-localization following ISO or S1P stimulation (Figure 1B). In contrast, as shown in
Figure 1C, in GRK-β1AR cells, ISO stimulation only induced β1AR but not S1PR1
internalization. On the other hand, S1P stimulation induced S1PR1 downregulation with no
effect on β1AR localization. Interestingly, ISO or S1P induced a similar significant increase
in pERK levels in all cell subtypes (Figure 1A–B–C). To better determine whether β1AR
and S1PR1 form stable complexes, β1AR and S1PR1 were expressed at same level in
HEK293 cells and then a co-immunoprecipitation (Co-IP) assay was performed. Notably, as
shown in Supplemental Figure 1, IP of S1PR1 resulted in a Co-IP of β1AR in the absence
(NS) or in presence of ISO or S1P, confirming our hypothesis of a direct receptor-receptor
interaction.
To further investigate how GRK-dependent phosphorylation was involved in the cross-talk
between β1AR and S1PR1, we also used a mutated form of S1PR1 (S1PR1-Δ32) lacking
GRK2 phosphorylation sites15. As shown in supplementary Figure 2A, S1PR1-Δ32 lost the
ability to be co-internalized with β1AR following agonists stimulation. Furthermore,
ERK1/2 phosphorylation resulted increased following ISO stimulation but at a lower extent
following S1P stimulation (Supplemental Figure 2A).
β1AR- and S1PR1-dependent GRK2 upregulation
Since it is known that both β1AR and S1PR1 are substrates of GRK2
phosphorylation13,14,15, and our data suggest a crucial role of this kinase in the co-
dependence of internalization of these two receptors, we further explored the potential role
of GRK2. A 2-fold increase in GRK2 levels in WTβ1AR cells stimulated for 12 hrs either
with ISO or S1P, was observed (Figure 2A). In PKA-β1AR cells, ISO or S1P stimulation
resulted in blunted, yet significant, GRK2 upregulation (Figure 2B). Importantly,
GRK-β1AR cells showed enhanced GRK2 expression only following S1P administration
(Fig. 2C).
In vitro protective role of S1PR1 on deleterious β1AR overstimulation
It is known that both β1AR and S1P are able to induce cardiomyocyte hypertrophy24,25.
Therefore, we tested the effects of chronic ISO and S1P administration in vitro in H9c2 cells
stimulated for 48 hrs in absence or presence of the β1AR antagonist metoprolol or the
S1PR1 selective antagonist W146. Treatment with both agonists resulted in a consistent
increase of cell surface area indicating a hypertrophic response that was blocked with the
respective antagonist (metoprolol or W146) (Figure 3A). Notably, only ISO induced an
increase in cardiomyocytes apoptosis (Figure 3B). This apoptotic response in ISO stimulated
cells was prevented by metoprolol pre-treatment (Figure 3B). Interestingly, S1P induced a
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robust hypertrophic response and blunted apoptotic reaction in metoprolol pre-treated cells
(Figure 3A–B). Reciprocally, ISO stimulation in the presence of S1PR1 antagonist did not
induce an hypertrophic response but increased apotosis (Figure 3A–B).
In vivo reciprocal β1AR and S1PR1 downregulation
As widely demonstrated2,17,18, chronic in vivo ISO administration induces cardiac
hypertrophy, pathology and strong cardiac β1AR plasma membrane downregulation. Thus,
to determine whether our in vitro findings could be translated in vivo, we analysed S1PR1
density in crude myocardial membrane preparations from mice after 7 days of ISO
administration. As expected, after chronic ISO stimulation mice exhibited a significant
increase in Heart to Body Weight (HW/BW) ratio (Figure 4A), LV-septum thickness (Figure
4B) and a robust cardiac GRK2 upregulation compared to untreated mice (Figure 4C).
Notably, 7 days of ISO administration resulted in a S1PR1 downregulation at the plasma
membrane level (Figure 4D).
In addition, in order to evaluate whether S1PR1-selective agonist was able to induce a
similar β1AR downregulation in vivo, we treated mice for 7 days (via daily intraperitoneal
injections) with the S1PR1 agonist, SEW2871 (Supplemental Figure 3). Interestingly, SEW-
treatment resulted in a consistent increase in HW/BW ratio (Supplemental Figure 3A) and in
a strong increase in GRK2 protein levels (Supplemental Figure 3B) compared to untreated
mice. Consistently, with our in vitro observations, this S1PR1 selective agonist resulted in a
robust decrease in β1AR cardiac plasma membrane levels compared to untreated group
(Supplemental Figure 3C).
Cardiac S1PR1 membrane downregulation during heart failure
Since our data show that S1PR1 internalization occurs in vitro as well as in vivo following
chronic ISO stimulation, we studied potential S1PR1 dysregulation in a clinically relevant
experimental model of HF, a pathological condition characterized by a sustained elevation
of circulating catecholamines. Accordingly, plasma membranes were extracted from LV
lysates of 8 week post-myocardial infarction (post-MI) rats. Importantly, we found a
significant down-regulation of S1PR1 in HF rats compared to control (Figure 5A).
Accordingly, in order to assess whether S1PR1 down-regulation during HF was induced by
an increase in S1P levels we performed an ELISA assay for S1P on blood serum and an
immunoblots on LV lysates to assess the expression of Sphingosine kinase 1 (SphK1) in our
HF and SHAM groups (Supplemental Figure 4A–B). Notably, both S1P circulating levels
and SphK1 expression were robustly reduced in HF group compared to SHAM, proving that
S1PR1 behaves similarly to β1AR in a significant pathophysiological setting such as HF22.
In contrast, S1PR1 gene therapy was able to restore SphK1 expression at the levels observed
in sham and to increase S1P circulating levels compared to HF control group.
In vivo S1PR1 gene therapy
Since we have demonstrated that S1PR1 signaling is beneficial in cardiomyocytes in vitro,
and that this receptor is down-regulated in our animal model of post-MI HF, we next
explored the effects of long-term S1PR1 receptor overexpression during HF. Adult male
Sprague-Dawley rats underwent MI (n=30) or SHAM operation (n=10). 8 weeks post-
surgery HF rats were randomly assigned to one of the following group: 1) HF Saline (HF,
n=10); 2) HF Adeno-associated type 6-GreenFluorescent Protein (HF-rAAV6-GFP, n=10);
3) HF rAAV6-S1PR1-GFP (HF-rAVV6-S1PR1, n=10). A baseline echocardiogram was
performed in all groups one day before treatment onset, to confirm the presence of similar
levels of LV dysfunction before gene delivery. All groups were then studied over the course
of 12 additional weeks (20 weeks after MI) (Figure 5B), and all assays in the HF groups
were compared with a control SHAM-operated group that received neither MI nor gene
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transfer. At 12 weeks after gene delivery, both transgenes (S1PR1 and GFP) were robustly
expressed in the LV, as assessed by immunohistochemistry (Figure 5C). Consistently, RT-
PCR analysis (Figure 5D) and immunoblots (Figure 5E) confirmed the expression of the
human S1PR1 in the heart of rAAV6-S1PR1 group and of GFP in both hearts of rAAV6-
S1PR1 and −GFP groups. As shown in Figure 5F, 20 weeks following MI, cardiac rAAV6-
S1PR1 gene therapy resulted in restoration of plasma membrane S1PR1 at the level
observed in SHAM animals.
Effects of S1PR1 overexpression on in vivo cardiac function at 12 weeks after gene
delivery
Eight weeks after experimental MI, LV ejection fraction (EF) was dramatically decreased
and end-diastolic diameter was increased as expected (Figure 6A–B). Treatment with GFP
or saline had no impact on cardiac performance with a further deterioration of cardiac
function 12 weeks later. On the other hand, S1PR1 overexpression ameliorated LV
contractility. In fact, EF was significantly increased in S1PR1 infected rats compared to HF
controls (Figure 6B). Adverse LV remodeling as measured by ventricular dilatation also
progressed further in saline and GFP groups, and this was prevented by S1PR1 gene
delivery. As expected no differences in infarct size were observed among all HF groups
since gene therapy was performed 8 weeks post-MI when the infarct scar was completely
established (data not shown). Of note, S1PR1 gene delivery affected the immune response as
observed by Hematoxylin/Eosin staining of cardiac sections. In fact, S1PR1 overexpression
resulted in a reduced infiltration of immune cells compared to HF control group
(Supplemental Figure 5A). Interestingly, S1PR1 overexpression in the LV induced a
consistent decrease in heart rate. LV invasive hemodynamic analysis in rats performed at the
end of the study period (12 weeks after gene delivery) showed significant decreases in +dP/
dt and −dP/dt in all HF groups compared to SHAM, proving HF-related reduction in LV
contractility and relaxation (Table 1 and Figure 6C). LV systolic pressure was significantly
reduced, whereas LV end-diastolic pressure was significantly increased in all HF groups
compared to SHAM (Table 1). Cardiac S1PR1 overexpression significantly improved LV
contractility and relaxation 12 weeks after treatment (Table 1 and Figure 6C). Furthermore,
S1PR1 gene delivery increased LV systolic pressure and decreased end-diastolic pressure
compared to HF control groups (Table 1). Notably, total plasma membrane βAR density was
completely restored in rAAV6-S1PR1 hearts compared with HF controls (Figure 6D).
Accordingly, S1PR1 infected rats showed significantly improved LV +dP/dt and LV −dP/dt
after maximal βAR stimulation by ISO (Table 1 and Figure 6C).
Effect of S1PR1 on cardiac remodeling and angiogenesis
The beneficial effect of S1PR1 overexpression on cardiac function was accompanied by a
hypertrophic response of the failing heart. This observation was evident at
echocardiographic evaluation where we found increased anterior wall diastolic thickness
(AWd) and posterior wall diastolic thickness (PWd) in S1PR1 rats compared to HF controls
(Table 1). Consistently, HW/BW ratio was significantly higher in hearts treated with S1PR1
compared to GFP and saline treated groups (Table 1). Importantly, the S1PR1-dependent
increase of LV mass was accompanied by significant decrease of LV systolic and diastolic
internal diameter compared to rAAV6-GFP HF hearts, thus indicating that S1PR1 gene
therapy induced a compensatory hypertrophic response able to contrast LV dilatation. In
accordance with previous observations reported by us and others25,26, this adaptive LV
remodeling was associated with a significant growth of cardiac capillary network. In fact,
S1PR1 gene delivery resulted in a significant increase in capillary density compared to HF
groups and a complete recovery of myocardial blood flow that was indistinguishable from
SHAM (Figure 7A–B). At the molecular level, we investigated the effects on Akt activation
since this kinase is one of the major pro-angiogenetic molecules involved in S1PR1
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signaling27,28. Notably, S1PR1 down-regulation was associated with a robust reduction in
Akt activation compared to SHAM (Supplemental Figure 6A). Of note, S1PR1 gene therapy
was able to enhance Akt activation (Supplemental Figure 6A).
Discussion
Heart failure is a major and growing public health problem affecting 1–6% of the US
population29. It is a disease characterized by LV dysfunction associated with a complex of
symptoms that relate to inadequate perfusion of tissues and pulmonary congestion. One of
the consequences is the activation of the SNS, which plays a crucial role in adapting
circulatory homeostasis to changes in environment. Further, circulating levels of
catecholamines are increased in HF in proportion to the severity of the disease30. However,
sympathetic hyperactivity can also initiate or accelerate cardiac dysfunction and provoke
major cardiovascular events, thus justifying why HF patients with higher plasma levels of
norepinephrine have the most unfavorable prognosis31. These observations have led to the
hypotheses that sympathetic activation may play an important role in HF progression8,32,33
and that pharmacological interference with this system can produce hemodynamic and
clinical benefits34.
Currently, some of the most effective treatments for HF target β1AR and β2AR and
angiotensin II type IA receptor, which are both GPCRs4. Several experimental evidences
have demonstrated that GPCRs can actually interact and can be reciprocally regulated. For
instance, it has been shown that the β1AR is able to transactivate EGFR, conferring a β-
arrestin dependent cardioprotective effect2. These data have led to hypothesize the
development of new therapies for HF that would be able not only to antagonize harmful
cardiac signaling, but also potentiate the beneficial pathways35. In that regard, a deeper
understanding of the signaling mechanisms underlying the development and progression of
heart failure is absolutely needed.
Our data show, for the first time, a direct interaction between β1AR and S1PR1,
representing dynamic regulation present between two important and predominant GPCRs in
the heart that appears to have significant physiological effects. Using HEK293 cells
overexpressing the WTβ1AR, and transiently transfected with S1PR1, we demonstrated in
vitro that either ISO or S1P stimulation induce a dual-internalization with a cytosolic co-
localization of both β1AR and S1PR1. As a functional consequence, ERK activation occurs.
Importantly, we also demonstrated that both β1AR and S1PR1 are able to form a stable
complex and that the reciprocal downregulation of the two receptors occurs only in presence
of agonist-dependent GRK2 activation. In fact, we examined the molecular mechanisms of
such interaction, and interestingly found that the absence of GRK-phosphorylation sites but
not the absence of PKA-phosphorylation sites on the β1AR abolished the cross talk between
the two receptors. Similarly, the lack of GRK2-phosphorylation sites on S1PR1 inhibited the
reciprocal down-regulation between β1AR and S1PR1 following agonists stimulation.
Therefore, GRK2 seems to be a nodal regulator of the cellular response to both
cathecolamines and S1P and it is able to modulate the phosphorylation and the reciprocal
internalization of both β1AR and S1PR1.
It is known that β1AR is a very important regulator of cardiac function both in physiological
and pathophysiological settings36,37 and its action can become deleterious over time. An
important role has also been recently shown for the S1PR1. In fact, this receptor can mediate
an hypertrophic response in neonatal rat cardiomyocytes38 and it is cardioprotective for
adult cardiomyocytes under hypoxia10 and in the intact heart exposed to myocardial
infarction39,40,41,42. Our data confirm S1PR1 ability to mediate hypertrophy in cultured cells
as well as the β1AR. However, while β1AR is also able to induce significant apoptosis, this
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is not the case of S1PR1. More interestingly, the apoptotic response to ISO stimulation
increases if the S1PR1 receptor is blocked. Our data demonstrate that S1PR1 signaling
results to be cardioprotective, in particular during a sustained catecholamine stimulation
which reproduces pathological condition such as HF. In fact, our demonstration that S1PR1
is downregulated in the pathological cardiac hypertrophy induced by ISO injection in mice,
which is known to predispose to cardiac dysfunction, confirms that S1PR1 inactivation
could have a role in the progression toward HF. More interestingly, we show that in a rat
model of post-ischemic HF, S1PR1 plasma membrane levels are significantly
downregulated. Further, our results showed that the observed S1PR1 down-regulation was
not correlated to an S1P increase. In fact, this molecule was even strongly reduced in blood
serum of post-MI HF mice compared to SHAM, strengthening our hypothesis of an active
role of catecholamine overstimulation in vivo on reciprocal down-regulation between β1AR
and S1PR1.
Of note, rAVV6 gene therapy, as previously described43, allowed us to obtain the long-term
and stable myocardial gene expression of rAAV6-S1PR1 cardiac gene transfer. For the first
time, we directly investigated the therapeutic effects of 12 weeks expression of S1PR1 in the
failing heart. We were able to demonstrate that rAAV6-S1PR1 gene-delivery restored
S1PR1 plasma membrane levels and its signaling, observed by a consistent increase in
SphK1 expression in the heart and S1P active secretion in blood serum, and exerts an
important functional and structural cardiac recovery, improving cardiac function and
blocking the negative remodelling in our post-MI rat HF model. Three months after gene
delivery we found significantly increased LV EF, dP/dt and systolic blood pressure whereas
LV-end diastolic diameter and pressure were decreased in comparison to the control HF
animals.
The beneficial effects of S1PR1 gene therapy were also evident on post-MI βAR
dysfunction. In fact, maximal inotropic responses during βAR stimulation were almost
completely restored after S1PR1 gene delivery. It is reasonable to hypothesize that the
favorable action of S1PR1 overexpression in the post-MI heart is probably due to either a
direct cardioprotective effect and to an increase of the angiogenic response that promotes an
adaptive, angiogenesis-dependent LV hypertrophy instead of transitioning to a maladaptive
state. Consistent with this, S1PR1 gene delivery induced the activation of Akt signaling,
preventing capillary rarefaction and completely restoring myocardial blood flow in our
experimental groups. Taken together, our data show that S1PR1 downregulation, probably
induced by an excessive catecholamine stimulation during HF, can be responsible for the
progression toward a further decrease of cardiac performance. Importantly, in the present
study we focused on S1PR1 that represents the S1PR subtype with highest expression in the
heart and further studies will be needed to uncover potential relevant roles of S1PR2 and
S1PR3 in HF. In conclusion, the ability of S1PR1 gene delivery to prevent LV failure in a
setting of established myocardial damage, confers to this molecule the potential to be a
candidate for HF treatement.
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Clinical Perspective
In chronic heart failure (HF), sympathetic nervous system overdrive induces the up-
regulation of G protein-coupled receptor kinase 2 (GRK2) with a consequent β-
adrenergic receptor (βAR) down-regulation/desensitization. Importantly in failing
myocardium βAR dysregulation is clinically seen by loss of inotropic reserve. Currently,
β-blockers represent a solid “pillar” in HF therapy which at molecular level efficiently,
counteract both βAR down-regulation and GRK2 up-regulation. Noteworthy, GRK2
inhibition represent a new promising strategy to rescue the failing heart and we have
recently recently demonstrated that in some animal models could be used as substitution
or in conjunction with β-blockers. GRK2 inhibition may be effective in HF interfering
with other intracellular processes. The present study provides the first evidence of a
direct and GRK2-dependent interaction between β1AR and S1PR1. We show that the
reciprocal down-regulation between these two predominant GPCRs in the heart, appears
to have significant physiological effects on cardiac hypertrophy, apoptosis and
remodeling. Clinically, HF-related S1PR1 down-regulation worsens left ventricular
dysfunction in a setting of established myocardial damage. Noteworthy, we show that the
increase of S1PR1 density, through gene therapy, in failing cardiomyocytes may
represent a novel therapeutic strategy for HF. This study clearly opens a new chapter in
the understanding of the molecular mechanisms involved in HF, demonstrating that
beside the well documented therapeutic effects of βAR signalling “resensitization” in HF
via GRK2 inhibition or beta-blockade, a new field of research could be the reconstitution
of S1PR1 cardioprotective signaling as a new therapeutic target along with other
unexplored signaling pathways.
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Figure 1.
GRKs-phosphorylation sites removal inhibits the cross-talk between β1AR and S1PR1.
HEK293 cells stably expressing WTβ1AR-Flag (A), PKA-β1AR-Flag (B), GRK-β1AR-Flag
(C) and transfected with S1PR1-GFP, were pre-treated with β2AR antagonist ICI-118,551-
HCl (ICI, 10 μM), then were stimulated with (−)-isoproterenol bitartrate (ISO) (1 μM) or
sphingosine 1-phosphate (S1P) (250 nM) for 30 min and compared with unstimulated (NS).
Representative panels of S1PR1-GFP and β1AR-Flag immunofluorescence images, showing
cumulative data of multiple independent experiments in WTβ1AR-Flag+S1PR1-GFP (A),
the PKA-β1AR-Flag+S1PR1-GFP (B) or the GRK-β1AR-Flag+S1PR1-GFP (C). Arrows
indicate receptor internalization; Representative immunoblots showing ERK1/2 activation
following 5 min of stimulation with ISO (1 μM) or S1P (250 nM) in WTβ1AR-Flag (A),
PKA-β1AR-Flag (B), GRK-β1AR-Flag (C). GAPDH was used as loading control.
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Figure 2.
Reduced effect on GRK2 upregulation following GRKs-phosphorylation sites removal in
β1AR. Representative immunoblots (upper panels) and dot plots (lower panels) showing
GRK2 levels following 12 hours of stimulation with ISO (1 μM) or S1P (250 nM) in
WTβ1AR-Flag (A), PKA-β1AR-Flag (B), GRK-β1AR-Flag (C). GAPDH was used as
loading control (GRK2 levels Fold over NS mean); Statistical significance between groups
was determined by exact tests (Mann-Whitney and Kruskal-Wallis) followed by Bonferroni
post-hoc correction. Barred diamond represents the median. N= 9 for each group. *p<0.05
vs. NS; †p<0.05 vs. ICI/ISO.
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Figure 3.
Physiological role for β1AR and S1PR1 interaction. Representative images (upper panels)
and dot plots (lower panels) showing (A) hypertrophic (relative cell surface area) and (B)
apoptotic (Tunel positive nuclei) response in H9c2 cells transfected with cDNA encoding
for S1PR1-GFP and the mouse WTβ1AR-Flag. Cells were pre-treated with ICI (10 μM) and
stimulated with ISO (10 μM) or S1P (250 nM); cells pre-treated with β1AR antagonist
Metoprolol tartrate (MET, 1μM) or S1PR1 selective antagonist W146 (10 μM) were then
treated with ISO (10 μM) or S1P (250 nM) for 48 h. Each experiment was independently
repeated 3 (panel A) and 4 (panel B) times. Statistical significance between groups was
determined by one-way ANOVA followed by Bonferroni post-hoc correction. Barred
diamond represents the mean. *p<0.05 vs NS; † p<0.05 vs. all.
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Figure 4.
In vivo chronic ISO treatment (7 days) resulted in a GRK2 upregulation and an S1PR1
plasma membrane downregulation. A. Representative images (upper panel) of sirius red
staining of mouse cardiac sections from SHAM and ISO7d groups (25X) and dot plots
(lower panel) showing the heart weight/body weight (HW/BW) ratio in SHAM and ISO 7d:
B. Representative serial M-mode echocardiographic tracings (upper panel) before ISO and
following ISO7d and dot plots (lower panel) showing Septum thickness; C. Representative
immunoblots (upper panels) and dot plots (lower panel) of GRK2 levels in ISO7d groups
compared to SHAM (GRK2 levels Fold over SHAM mean). D. Representative immunoblots
(upper panels) and dot plots (lower panel) of S1PR1 membrane levels in crude LV
membrane preparations from SHAM and ISO7d mice. ACTIN was used as loading control.
GAPDH and Na+/K+ATPase were used as membrane purification control (S1PR1 levels
Fold over SHAM mean). Statistical significance between groups was determined by Mann-
Whitney exact test. N= 5 for each group. Barred diamond represents the median. *p<0.05 vs
SHAM.
Cannavo et al. Page 17
Circulation. Author manuscript; available in PMC 2014 October 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
The overexpression of S1PR1 restores the receptor plasma membrane levels impaired during
heart failure. A. Representative immunoblots (upper panel) and dot plots (lower panel)
showing S1PR1 membrane density in crude LV membrane preparations from SHAM and
HF rats. ACTIN was used as loading control (S1PR1 levels Fold over SHAM mean).
Statistical significance between groups was determined by Mann-Whitney exact test. N= 5
for each group. Barred diamond represents the median. *p<0.05 vs SHAM; B. Overall
design of 20-week study of S1PR1 gene delivery in HF rats; C. Representative images of
S1PR1 and GFP immunohistochemistry stainings on cardiac sections from HF, HF+rAVV6-
S1PR1 and HF+rAAV6-GFP rats, performed at the end of the study period; D.
Representative images (upper panel) of RT-PCR on cardiac total RNA lysates from HF, HF
+rAAV6-S1PR1 and HF+rAAV6-GFP rats, showing the overexpression of transgenic
human S1PR1 (hS1PR1) and GFP; E. Representative immunoblots (lower panel) showing
the transgenic expression of human S1PR1 (hS1PR1) and GFP in HF, HF+rAAV6-S1PR1
and HF+rAAV6-GFP rats; F. Representative immunoblots (upper panels) and dot plots
(lower panel) of S1PR1 membrane density in crude LV membrane preparations from
SHAM, HF and HF+rAAV6-S1PR1 rats. ACTIN was used as loading control (S1PR1 Fold
over SHAM mean). Statistical significance between groups was determined by exact tests
(Mann-Whitney and Kruskal-Wallis) followed by Bonferroni post-hoc correction. N= 5 for
each group, except N=7 for HF+rAAV6-S1PR1 group. Barred diamond represents the
median. *p<0.05 vs SHAM ; †p<0.05 vs HF.
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Figure 6.
rAAV6-S1PR1 gene therapy at 12 weeks after MI ameliorates cardiac function. Bar graphs
showing cardiac parameters measurement at 12 weeks after MI and/or after 12 weeks of
treatment. A. Data are presented as mean ± SEM; Statistical significance between groups
was determined LV internal diameter at diastole (LVIDd) measured by echocardiography 12
weeks after MI and after 12 weeks of treatment; B. Ejection Fraction (EF) as measured by
echocardiography 12 weeks after MI (A) and 12 weeks after in vivo gene delivery; C.
Average LV +dP/dt and LV −dP/dt values evaluated under basal conditions and after
maximal isoproterenol stimulation; D. β1AR density in cardiac homogenates purified from
hearts of all experimental groups performed at the end of the study period. Statistical
significance between groups was determined by repeated measure ANOVA with Bonferroni
post-hoc correction (panels A, B and C) and, by one-way ANOVA with Bonferroni post-hoc
correction (panel D; barred diamond represents the mean). N= 10 for each group. *p<0.05
vs SHAM; †p<0.05 vs HF.
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Figure 7.
Beneficial effects of S1PR1 gene delivery on cardiac angiogenesis. A. Total myocardial
blood flow measured at basal condition and after maximal coronary dilatation; B. Bar graph
showing capillary density on mm2 ratio evaluated by Lectin Bandeiraea simplicifolia I (BS-
I) staining of capillaries in cardiac section obtained from HF control groups and HF plus
rAAV6-S1PR1. Statistical significance between groups was determined by repeated
measure ANOVA followed by Bonferroni post-hoc correction. N= 10 for each group.
*p<0.05 vs SHAM; †p<0.05 vs HF.
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Table 1
Echocardiographic, hemodynamic and physical parameters at 12 weeks after rAAV6-Mediated Cardiac Gene
Delivery
Echocardiography SHAM HF HF+AVV6-S1PR1
FS% 37.4±0.7 13.6±0.8* 19.7±1.1*†
EF% 65.4±0.9 26.9±1.6* 38.3±1.8*†
Awd 1.68±0.05 1.38±0.06* 1.69±0.04†
Aws 2.66±0.09 1.79±0.09* 2.34±0.13*
LVIDd 8.5±0.2 10.92±0.18* 10±0.18*†
LVIDs 5.42±0.14 9.46±0.2* 8.08±0.19*†
PWd 1.73±0.04 2.03±0.06* 2.43±0.09*†
PWs 2.84±0.1 2.52±0.15 2.95±0.1
LV catheterization, basal SHAM HF HF+AVV6-S1PR1
HR, bpm 330.5±11.6 322±9.6 290±8.1*†
LV dP/dt, mm Hg/s 6494.8±244 4461±179.8* 5260±245.7*†
LV −dP/dt, mm Hg/s 6968±327.8 3626±106.1* 4251.4±128.8*†
LVEDP, mm Hg 2.2±0.3 13.5±1.1* 7.7±0.9*†
LVESP, mm Hg 132.2±3.6 104.1±4.9* 107.8±3.3*
Isoproterenol (333 ng/kg BW)
HR, bpm 400±20.7 381±12.7 341.1±4.3*†
LV dP/dt, mm Hg/s 15316±416.8 7476.5±140* 10036.1±272.4*†
LV −dP/dt, mm Hg/s 8629.8±365 5144.9±166.3* 7297.1±244.1*†
LVEDP, mm Hg 1.4±0.8 11.4±0.9* 6.6±0.7*†
LVESP, mm Hg 126.7±2 99.7±2.7* 110.8±3.2*†
BW, Kg 0.46±0.01 0.48±0.01 0.47±0.01
HW/BW, g/Kg 1.12±0.02 3.03±0.08* 3.55±0.13*†
Data are presented as mean ± SEM. Effect of S1PR1 gene therapy on LV function evaluated at 12 weeks after gene delivery is shown. In vivo
Ejection fraction (EF), Anterior wall diastolic thickness (Awd), Anterior wall systolic thickness (Aws), LVIDd, LV internal diameter at systole
(LVIDs), PWd, Posterior wall systolic thickness (PWs), Heart rate (HR), LV dP/dt, LV −dP/dt, LV end-diastolic pressure (LVEDP), LV end-
systolic pressure (LVESP), were assessed in: SHAM (n=10), HF+saline (n=10), HF+rAAV6-S1PR1 (n=10) and HF+rAAV6-GFP (n=10) rats.
Ratio of heart weight to body weight and fractional shortening (FS%) was also measured in all groups ANOVA analysis and Bonferroni test were
used between all groups.
*p<0.05 vs SHAM;
†p<0.05 vs HF control groups.
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